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Abstract
Background: Presence of microvascular obstruction (MVO) derived from cardiac magnetic resonance (CMR) imaging is
among the strongest outcome predictors after ST-segment elevation myocardial infarction (STEMI). We aimed to
investigate the comparative predictive values of different biomarkers for the occurrence of MVO in a large cohort of
reperfused STEMI patients.
Methods: This study included 128 STEMI patients. CMR imaging was performed within the first week after infarction to
assess infarct characteristics, including MVO. Admission and peak concentrations of high-sensitivity cardiac troponin T
(hs-cTnT), creatine kinase (CK), N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein
(hs-CRP), lactate dehydrogenase (LDH), aspartate transaminase (AST) and alanine transaminase (ALT) were measured.
Results: MVO was detected in 69 patients (54%). hs-cTnT, CK, hs-CRP, LDH, AST and ALT peak concentrations showed
similar prognostic value for the prediction of MVO (area under the curve (AUC) = 0.77, 0.77, 0.68, 0.79, 0.78 and 0.73, all
p > 0.05), whereas the prognostic utility of NT-proBNP was weakly lower (AUC = 0.64, p < 0.05). Combination of these
biomarkers did not increase predictive utility compared to hs-cTnT alone (p = 0.349).
Conclusions: hs-cTnT, CK, hs-CRP, LDH, AST and ALT peak concentrations provided similar prognostic value for the
prediction of MVO. The prognostic utility of NT-proBNP was lower. Combining these biomarkers could not further
improve predictive utility compared to hs-cTnT alone.
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Background
The broad implementation of early primary percutaneous
coronary intervention (PPCI) for acute ST-segment eleva-
tion myocardial infarction (STEMI) resulted in a significant
improvement of clinical outcomes [1, 2]. Nevertheless,
despite restoration of epicardial blood flow, adequate myo-
cardial reperfusion cannot be achieved in a significant por-
tion of patients-a phenomenon called ‘no reflow’ [3]. Three
distinct pathophysiological processes are critical in the
development of ‘no reflow’ after PPCI for STEMI: distal
embolization, ischemia-reperfusion injury, and individual
susceptibility [4].
Today cardiac magnetic resonance (CMR) imaging
allows a comprehensive infarct characterization includ-
ing the assessment of microvascular injury [5]. Micro-
vascular injury detected by the use of CMR imaging is
generally called ‘microvascular obstruction’ (MVO) [6].
In the so far largest prospective, multicenter study com-
prising more than 700 STEMI patients MVO provided
independent and incremental prognostic value for the
occurrence of major adverse cardiac events within 1 year
after infarction [7]. In the study by Cochet et al. MVO
provided 84% sensitivity and 65% specificity for the pre-
diction of major adverse cardiac events 1 year after
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reperfused AMI [8]. Another study in STEMI patients
proved MVO as an independent outcome predictor
during a median long-term follow-up of 52 months [9].
Importantly, presence of MVO provides incremental in-
formation over traditional outcome parameters like left
ventricular (LV) ejection fraction and infarct size (IS)
[3, 10]. Identification of MVO, therefore, could allow
for ideal risk stratification in the early stage after acute
STEMI, but is still hampered due to the limited avail-
ability of CMR in clinical routine [11]. A biomarker
model for prediction of MVO, which could easily be
applied in a broad range of STEMI patients, might pro-
vide a practicable and cost effective alternative to CMR.
An association between serially measured cardiac tropo-
nin concentrations and CMR derived MVO has previously
been reported for this patient cohort [12, 13]. However,
these studies were hampered either due to a small sample
size or the use of non-high-sensitivity troponin assays.
Furthermore, N-terminal pro-B-type natriuretic peptide
(NT-proBNP) levels obtained upon hospital admission for
acute STEMI might be predictive for the presence of
MVO [14]. However, limited data are available regarding
the relation of CMR derived MVO and other clinically
available biomarkers apart from cardiac troponin and NT-
proBNP [12–14]. Therefore, the aims of the present study
were 1) to investigate the association of CMR-determined
MVO with admission and peak concentrations of
routinely measured laboratory markers (high-sensitivity
cardiac troponin T (hs-cTnT), creatine kinase (CK), NT-
proBNP, high-sensitivity C-reactive protein (hs-CRP),
lactate dehydrogenase (LDH), aspartate transaminase
(AST) and alanine transaminase (ALT)), 2) to assess the
prognostic value of these biomarkers for the prediction of
MVO and 3) to analyze the prognostic utility of a com-
bined biomarker panel.
Methods
Study population
One hundred and twenty-eight patients with first STEMI
admitted to our coronary care unit were recruited to this
single-center, prospective, observational study. Diagnosis
of STEMI was based on the redefined ESC/ACC commit-
tee criteria [15]. Inclusion criteria were reperfusion by
PPCI and no contraindication for CMR examination. Ex-
clusion criteria were age below 18 years, an estimated
glomerular filtration rate < 30 ml/min/1.73 m2 and Killip
class ≥ 3 at admission. Data on patient characteristics were
acquired with the help of a standardized questionnaire
during hospitalization. Ischemia time was defined as
the delay from symptom onset to the time-point of first
balloon-inflation. The study complies with the ethical
guidelines of the 1975 Declaration of Helsinki and was
approved by the local ethics committee of Medical
University of Innsbruck. Written informed consent was
obtained from all patients before inclusion into the study.
Biochemical analysis
Blood samples were taken from a peripheral vein and im-
mediately analyzed at our central laboratory. High-
sensitivity cardiac troponin T (hs-cTnT) concentrations
were measured using a fifth-generation high-sensitivity
assay (Roche Diagnostics, Mannheim, Germany) [16, 17].
The analytical limit of detection was 5 ng/l and the 99th
percentile upper reference limit was 14 ng/l. The 10%
coefficient of variation was 13 ng/l. Plasma NT-proBNP
concentrations were measured as described in detail previ-
ously [18, 19]. The analytical limit of detection of NT-
proBNP was 5 ng/l. Creatine kinase (CK), high-sensitivity
C-reactive protein (hs-CRP), lactate dehydrogenase
(LDH), aspartate transaminase (AST), and alanine trans-
aminase (ALT) activities were measured by routine assays
as described previously [16, 18].
hs-cTnT concentrations were determined on admis-
sion, subsequently three times during the first 24 h and
then daily until day 4 or discharge. All other biomarkers
were measured on admission and subsequently once
daily up to day 4 after PPCI or discharge. Biomarker
peak concentrations are regarded as the highest values
in the concentration time-course.
Cardiac magnetic resonance imaging
All CMR scans were performed on a 1.5 Tesla Magnetom
Avanto scanner (Siemens, Erlangen, Germany). The im-
aging protocol has been described in detail previously
[12]. In brief, true fast imaging steady-state precession
(true-FISP) bright-blood sequences in the LV short axis
were acquired to assess LV function and morphology.
Image post-processing was performed using standard soft-
ware (ARGUS, Siemens). IS and presence of MVO were
derived from late gadolinium-enhanced images as previ-
ously described [9]. A threshold of + 5 standard deviations
was defined as ‘hyperenhancement’ [20]. MVO was de-
fined as a persisting area of hypoenhancement within
hyperenhanced myocardium [9].
Statistical analysis
Statistical analysis was performed using SPSS Statistics
22.0.0 (IBM, Armonk, NY, USA) and MedCalc 15.8
(Ostend, Belgium). To test for normal distribution (ND),
Shapiro-Wilk test was used. Continuous data are
expressed as mean ± standard deviation (SD) or as median
with interquartile range (IQR) as appropriate. Categorical
data are expressed as numbers with corresponding per-
centages. Pearson’s (if ND) or Spearman’s rank (if not ND)
correlation coefficients were calculated. Differences in
continuous variables between groups were calculated by
Student’s t-test, if ND. Otherwise, Mann-Whitney U test
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was used. To test for group-differences of categorical vari-
ables χ2-test was applied.
Receiver operator characteristics (ROC) analysis was
used to determine the predictive value (area under the
curve (AUC)) of biomarkers. Biomarkers which signifi-
cantly differed between patients with and without MVO
were included into ROC analyses. Binary logistic regres-
sion analysis was used as a statistical tool to combine
biomarkers as previously described [17]. The potentially
incremental information of a combined biomarker
model for the prediction of MVO was assessed by c-sta-
tistics. C-statistic results were compared using the
method previously described by DeLong et al [21]. Two-
tailed p-values < 0.05 were considered statistically
significant.
Results
Patients and infarct-related characteristics
Mean age of the study cohort was 58 ± 10 years; 12 pa-
tients (9%) were female. Baseline characteristics of the
study cohort are shown in Table 1. The median delay to
reperfusion was 220 min (IQR 155–417 min). Sixty-one
patients (48%) presented with anterior infarct location.
Seventy (56%), 34 (27%) and 21 (17%) patients showed
1-, 2- and 3-vessel disease according to coronary angiog-
raphy, respectively. Culprit only PPCI was performed in
all 128 patients. The culprit vessel was the right coron-
ary artery in 55 (43%), the left anterior descending artery
in 60 (47%), the left circumflex artery in 12 (9%) and the
ramus intermedius in 1 (1%) cases.
CMR scans were performed at a median of 3 days
after infarction (IQR 2–4 days). Median IS was 13%
(IQR 8–25%). Mean LVEF was 54 ± 10%. MVO was
present in 69 patients (54%).
Predictors of MVO
The delay from symptom onset to mechanical reperfu-
sion did not significantly differ between patients with
and without MVO (median = 213 min, IQR 149–
399 min vs median = 240 min, IQR 154–424 min; p =
0.469). Patients showing MVO were more likely to have
anterior infarcts compared to patients without MVO (n
= 39, 57% vs n = 22, 37%; p = 0.030). No association was
detected between the presence of MVO and the number
of diseased epicardial coronary arteries (p = 0.480).
Patients with presence of MVO showed significantly
higher IS (median = 21%, IQR 14–30% vs median = 9%,
IQR 3–13%; p < 0.001), EDV (153 ± 30 ml vs 140 ±
26 ml; p = 0.010), ESV (median = 73 ml, IQR 60–90 ml
vs median = 56 ml, IQR 44–72 ml; p < 0.001) and lower
LVEF (50 ± 9% vs 59 ± 10%; p < 0.001). The occurrence
of MVO did not significantly differ between patients
with one- and multivessel disease (p = 0.286).
Differences in biomarker levels between patients with
and without MVO are shown in Table 1.
hs-cTnT concentrations at admission provided an
AUC value of 0.61 (95% CI 0.52–0.69) for the prediction
of MVO (Fig. 1a). AUCs did not significantly differ be-
tween admission hs-cTnT, CK, NT-proBNP, hs-CRP,
LDH, AST and ALT (range 0.54, 95% CI 0.45–0.62 to
0.66, 95% CI 0.57–0.74; all p > 0.080).
Biomarker peak concentrations provided significantly
higher prognostic value for the prediction of MVO than
corresponding admission values (all p < 0.050) (Fig. 1).
Peak hs-cTnT concentrations provided an AUC of 0.77
(95% CI 0.68–0.85) for the prediction of MVO. Peak CK
(AUC = 0.77, 95% CI 0.69–0.84; p = 0.882), hs-CRP
(AUC = 0.68, 95% CI 0.60–0.76; p = 0.108), LDH (AUC =
0.79, 95% CI 0.71–0.86; p = 0.336), AST (AUC = 0.78,
95% CI 0.70–0.85; p = 0.517) and ALT (AUC = 0.73, 95%
CI 0.64–0.80; p = 0.312) showed similar AUCs for the
prediction of MVO compared to hs-cTnT. NT-proBNP
peak concentrations (AUC = 0.64, 95% CI 0.55–0.73)
exhibited significantly lower predictive utility compared to
peak hs-cTnT (p = 0.027), CK (p = 0.031), LDH (p = 0.007)
and AST (p = 0.016) concentrations. Optimal biomarker
cut-off values with corresponding sensitivity, specificity as
well as positive and negative predictive values for the pre-
diction of MVO are summarized in Table 2.
Including peak CK, NT-proBNP, hs-CRP, LDH, AST
and ALT concentrations additionally to peak hs-cTnT
levels did not result in a significantly higher accuracy for
the prediction of MVO (AUC = 0.79, 95% CI 0.71–0.87
vs AUC = 0.77, 95% CI 0.68–0.85; p = 0.349) (Fig. 2).
Discussion
This study for the first time comprehensively assessed the
incremental value of routine biomarkers for the prediction
of MVO after reperfused STEMI. The major findings were
that 1) presence of MVO was associated with higher
plasma concentrations of hs-cTnT, CK, hs-CRP, LDH, AST
and ALT; 2) biomarker peak concentrations provided sig-
nificantly higher prognostic value compared to admission
values; 3) peak concentrations of hs-cTnT, CK, hs-CRP,
LDH, AST and ALT showed similar prognostic value for
the prediction of MVO, whereas the prognostic utility of
peak NT-proBNP was lower; and 4) a model including peak
CK, NT-proBNP, hs-CRP, LDH, AST and ALT concentra-
tions additionally to hs-cTnT did not result in a
significantly higher accuracy for the prediction of MVO.
Inadequate myocardial reperfusion despite restoration of
epicardial coronary artery patency is attributed to micro-
vascular injury [22]. As previously shown, application of
modern antiplatelet therapy partly improves micro-
vascular perfusion [23]. Interestingly, removal of throm-
botic material by thrombus aspiration is ineffective in
improvement of myocardial reperfusion [24]. In the
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present study microvascular injury, defined as the pres-
ence or absence of CMR derived MVO, was detected in
54% of patients. This is in line with data from literature,
reporting an up to 60% rate of MVO in patients receiving
primary PCI for acute STEMI [3]. In the present study
culprit only revascularization was performed during PPCI.
Table 1 Patient characteristic of the overall cohort (n = 128) and after stratification for presence of MVO
Patient characteristics Overall cohort Presence of MVO
(n = 128) no (n = 59, 46%) yes (n = 69, 54%) p
Age, years 58 ± 10 57 ± 10 58 ± 10 0.925
Female, n (%) 12 (9) 8 (14) 4 (6) 0.223
Body mass index, kg/m2 26 (25–30) 27 (26–29) 26 (24–30) 0.522
Family history for AMI, n (%) 34 (27) 19 (32) 15 (22) 0.229
Current smokers, n (%) 63 (49) 28 (48) 35 (51) 0.727
RRsys, mmHg 125 ± 24 126 ± 23 123 ± 24 0.491
RRdia, mmHg 77 ± 15 78 ± 14 76 ± 15 0.309
Leucocyte count admission, G/l 11.7 (8.8–14.5) 11.5 (8.5–14.5) 12.0 (9.0–14.6) 0.649
Leucocyte count max, G/l 12.7 (10.8–15.8) 11.9 (10.3–15.2) 13.1 (11.7–16.4) 0.061
Total cholesterol, mg/dl 192 ± 44 185 ± 41 198 ± 47 0.108
Low-density lipoprotein, mg/dl 128 ± 42 123 ± 39 132 ± 44 0.230
High-density lipoprotein, mg/dl 42 (36–49) 40 (33–53) 43 (38–49) 0.320
Triglycerides, mg/dl 102 (78–151) 108 (80–163) 96 (77–142) 0.276
Plasma glucose admission, mg/dl 135 (115–161) 134 (116–163) 137 (112–160) 0.728
HbA1c, % 5.6 (5.4–6.0) 5.6 (5.4–6.1) 5.6 (5.3–5.9) 0.792
Creatinine admission, mg/dl 0.93 (0.82–1.05) 0.92 (0.76–1.07) 0.93 (0.83–1.04) 0.877
Creatinine max, mg/dl 1.04 (0.92–1.15) 1.03 (0.91–1.13) 1.06 (0.96–1.20) 0.261
hs-cTnT admission, ng/l 226 (29–2168) 201 (18–1388) 523 (34–4001) 0.036
hs-cTnT max, ng/l 5254 (2169–8735) 2866 (1026–5524) 6985 (4193–13639) <0.001
CK admission, U/l 353 (174–1182) 301 (148–862) 435 (207–2433) 0.048
CK max, U/l 2111 (1168–3674) 1228 (625–2323) 2776 (1749–4686) <0.001
NT-proBNP admission, ng/l 139 (66–511) 128 (66–360) 159 (71–687) 0.487
NT-proBNP max, ng/l 717 (184–1700) 360 (131–924) 1084 (312–2649) 0.003
hs-CRP admission, mg/dl 0.23 (0.11–0.61) 0.34 (0.15–0.66) 0.19 (0.09–0.56) 0.119
hs-CRP max, mg/dl 2.20 (0.96–4.56) 1.53 (0.64 3.02) 2.84 (1.68–7.44) <0.001
LDH admission, U/l 238 (196–364) 222 (182–301) 257 (207–493) 0.009
LDH max, U/l 593 (354–882) 358 (271–624) 742 (534–1182) <0.001
AST admission, U/l 82 (34–210) 57 (31–113) 126 (40–306) 0.008
AST max, U/l 239 (128–423) 151 (75–256) 340 (213–547) <0.001
ALT admission, U/l 37 (27–58) 31 (25–46) 45 (32–75) 0.003
ALT max, U/l 60 (42–87) 47 (32–69) 71 (52–111) <0.001
γGT admission, U/l 37 (25–52) 36 (26–50) 39 (23–59) 0.857
γGT max, U/l 40 (26–63) 37 (26–51) 41 (26–71) 0.482
AP admission, U/l 64 (53–79) 64 (52–80) 63 (54–76) 0.918
AP max, U/l 64 (53–81) 64 (52–83) 64 (54–81) 0.951
Total bilirubin admission, mg/dl 0.49 (0.38–0.69) 0.44 (0.37–0.65) 0.52 (0.40–0.73) 0.160
Total bilirubin max, mg/dl 0.62 (0.43–0.84) 0.60 (0.42–0.84) 0.62 (0.45–0.85) 0.668
MVO Microvascular Obstruction, AMI Acute Myocardial Infarction, RRsys Systolic Blood Pressure, RRdia Diastolic Blood Pressure, hs-cTnT High-Sensitivity Cardiac
Troponin T, CK Creatine Kinase, NT-proBNP N-terminal pro-B-type natriuretic peptide, hs-CRP High-Sensitivity C-Reactive Protein, LDH Lactate Dehydrogenase, AST
Aspartate Transaminase, ALT Alanine Transaminase, γGT Gamma-Glutamyltransferase, AP Alkaline Phosphatase
Bold data indicate statistical significance
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Thus, the impact of culprit only versus complete PPCI on
MVO could not be analysed in the present study. This im-
portant topic was recently investigated in a well-
conducted meta-analysis [25].
Besides its ability for accurate quantification of
ventricular function, morphology and infarct size, CMR
imaging has emerged as the most reliable imaging
modality to detect microvascular injury and is therefore
more and more used to define surrogate endpoints in
clinical trials [5, 26, 27]. There is strong evidence that
presence of MVO derived from late gadolinium-enhanced
images is the best CMR prognosticator regarding clinical
outcome after acute reperfused STEMI [3, 7]. Nevertheless,
its determination is hampered since CMR is still a rarely
available, expensive tool with restricted application in clin-
ical routine. Thus, implementation of a biomarker model,
which reliably allows for the prediction of MVO, is of
clinical and prognostic importance [28].
Fig. 1 Receiver operator characteristics (ROC) analyses comparing the predictive utility of admission and peak concentrations of a) hs-cTnT (AUC= 0.61,
95% CI 0.52–0.69 vs AUC= 0.77, 95% CI 0.68–0.85; p< 0.001), b) CK (AUC = 0.60, 95% CI 0.51–0.69 vs AUC = 0.77, 95% CI 0.69–0.84; p= 0.001), c) NT-proBNP
(AUC = 0.54, 95% CI 0.45–0.62 vs AUC = 0.64, 95% CI 0.55–0.73; p= 0.011) d) hs-CRP (AUC= 0.58, 95% CI 0.49–0.67 vs AUC= 0.68, 95% CI 0.60–0.76; p=NA),
e) LDH (AUC = 0.64, 95% CI 0.54–0.72 vs AUC = 0.79, 95% CI 0.71–0.86; p = 0.003), f) AST (AUC = 0.64, 95% CI 0.55–0.72 vs AUC = 0.78, 95%
CI 0.70–0.85, p= 0.005) and g) ALT (AUC= 0.66, 95% CI 0.57–0.74 vs AUC = 0.73, 95% CI 0.64–0.80; p= 0.049). hs-cTnT =High-Sensitivity Cardiac Troponin T;
CK = Creatine Kinase; NT-proBNP =N-terminal pro-B-type natriuretic peptide; hs-CRP =High-Sensitivity C-Reactive Protein; LDH= Lactate Dehydrogenase;
AST = Aspartate Transaminase; ALT = Alanine Transaminase
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In the present study, time to reperfusion did not
differ between patients with and without MVO. Pre-
sumably, this is due to the fact that microvascular
dysfunction might persist even after restoration of
epicardial blood flow [3, 29].
In line with data from literature, we detected a relation
between the presence of MVO and infarct size, LV sys-
tolic function and morphology [30–32].
An association between cardiac troponin concentra-
tions and CMR derived MVO has already been
reported by several studies [13, 33, 34]. Notably, the
significance of these studies is limited due to an
either small sample size and poorly defined patient
selection (STEMI and non-STEMI patients included)
or inconsistent reperfusion strategies. These limita-
tions were obviated in the study by Mayr et al, since
the relation between MVO and cardiac troponin
levels was confirmed in a large, well-defined cohort of
STEMI patients [12]. However, in this study a non-
high-sensitivity cardiac troponin T assay was used.
These assays provide lower prognostic value and are
associated with a longer troponin-blind period com-
pared to new-generation high-sensitivity assays [35].
This fact might particularly impact on the prognostic
utility of admission troponin levels.
Table 2 Biomarker cut-off values providing optimal sensitivity,
specificity as well as positive and negative predictive values
optimal cut-off sensitivity specificity PPV NPV
hs-cTnT max, ng/l 4387 75 68 73 70
CK max, U/l 1959 73 69 73 69
NT-proBNP max, ng/l 551 70 63 69 64
hs-CRP max, mg/dl 2,11 67 63 68 62
LDH max, U/l 496 82 70 76 77
AST max, U/l 224 75 71 75 71
ALT max, U/l 57 73 64 70 67
hs-cTnT High-Sensitivity Cardiac Troponin T, CK Creatine Kinase, NT-proBNP
N-terminal pro-B-type natriuretic peptide, hs-CRP High-Sensitivity C-Reactive
Protein, LDH Lactate Dehydrogenase, AST Aspartate Transaminase, ALT
Alanine Transaminase
Fig. 2 Receiver operator characteristics (ROC) curves of peak hs-cTnT concentrations and a combined biomarker model. Combination of biomarkers did
not result in significantly higher prognostic value for the prediction of MVO compared to hs-cTnT alone (AUC= 0.79, 95% CI 0.71–0.87 vs AUC= 0.77, 95%
CI 0.68–0.85; p= 0.349). hs-cTnT =High-Sensitivity Cardiac Troponin T; CK = Creatine Kinase; NT-proBNP=N-terminal pro-B-type natriuretic peptide; hs-CRP
=High-Sensitivity C-Reactive Protein; LDH= Lactate Dehydrogenase; AST = Aspartate Transaminase; ALT = Alanine Transaminase
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The present study extends previous findings, as we
investigated the predictive value of a broad range of rou-
tinely used laboratory markers including high-sensitivity
cardiac troponin T. All patients were exclusively reper-
fused by primary PCI, which is of importance since
reperfusion strategy might influence the occurrence of
MVO. Furthermore, high patient selection, as performed
in the present study, reduced the presence of co-
morbidities and consequently allowed to investigate
predictors of MVO independently of concomitant car-
diovascular disease.
Interestingly, peak concentrations of hs-cTnT, CK,
hs-CRP, LDH, AST and ALT provided similar prog-
nostic values for the prediction of MVO. This might be of
practical significance, in particular if high-sensitivity
troponin assays are not available in clinical routine. On
the other hand, combining hs-cTnT with other bio-
markers did not further improve the prognostic value
compared to a model solely including hs-cTnT.
To a certain extent, biomarkers investigated in the
present study have already been linked to clinical out-
come following AMI [36]. Moreover, in AMI patients
prognostic utility was even proved for novel, upcoming
biomarkers like galectin-3 [37]. Although an association
between biomarkers and hard clinical endpoints was
shown in previous studies, the present study adds some
causal relation, particularly since MVO is among the
strongest predictors of poor outcome after STEMI [7].
Besides its prognostic value, the therapeutic relevance
of MVO has been demonstrated in several studies. For
instance, modern antiplatelet therapy might improve
microvascular perfusion [23]. Moreover, in patients with
successfully reperfused AMI treatment with statins
before infarction was associated with a reduction of
microvascular injury [38].
Limitations
This is the largest CMR study investigating a compre-
hensive biomarker model for the prediction of MVO.
Nevertheless, further confirmation in larger cohorts is
necessary. Remarkably, sensitivity and specificity is less
than 80% for almost all biomarkers observed in the
present study. These biomarkers reflect myocardial
injury, haemodynamic alterations and inflammation.
However, the occurrence of MVO is a rather complex
pathophysiological process and, to a certain extent, a still
unresolved topic [39]. Possibly, the analysis of other, up-
coming chemical markers might further improve the
predictive value for the occurrence of MVO and should
be investigated in future studies [36, 40].
In the present study the proportion of female patients
was very low. Out of twelve female patients totally included
only four patients developed MVO. Therefore, gender-
specific, valid statistical analysis could not be performed.
However, the impact of gender on outcome in STEMI
patients has already been shown [41]. Thus, further studies
are needed investigating gender-specific differences in the
prediction of MVO.
The present study focused on the prediction of MVO
derived from CMR. Therefore, angiographic assessment
of myocardial blush grade and the relatively novel wire-
based technique to measure the index of microcircula-
tory resistance were not performed in this study [42].
Conclusions
hs-cTnT, CK, hs-CRP, LDH, AST and ALT peak concen-
trations provided similar prognostic value for the predic-
tion of CMR derived MVO in acute STEMI patients
reperfused by PPCI. In comparison, the prognostic util-
ity of peak NT-proBNP was lower. Combination of these
biomarkers did not add any additional prognostic value.
Since presence of MVO is among the strongest surro-
gate end-points for adverse clinical outcome after acute
STEMI, our findings could contribute to optimize risk
stratification early after the acute event.
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